After over six years of partnership, Adaptive Biotechnologies and Genentech are winding down their $2 billion strategic collaboration focused on personalized cancer cell therapies using T cell receptor (TCR) technology. The arrangement involved Adaptive identifying TCRs to target patient-specific neoantigens while Genentech managed therapy engineering, manufacturing, and clinical development. The termination was not prompted by safety issues. Adaptive remains focused on advancing its immune medicine portfolio and TCR-antigen prediction models to enable novel immunology applications and partnerships.